Swiss biotech Windward surges 68% in Nasdaq debut after $225 million raise
Windward Bio Group, a Basel-based developer of long-acting antibodies for asthma and COPD, priced its U.S. listing at $17 a share and watched it close at $28.50, one of the strongest biotech IPO debuts yet in a cautiously reopening new-issue market.

Windward Bio Group AG, a Swiss biotechnology company developing long-acting antibody treatments for asthma and other respiratory diseases, closed its first day of trading on the Nasdaq Global Select Market on Friday up 68 percent from its initial public offering price, one of the strongest debuts of this year's tentative recovery in biotech listings.
The Basel-based company priced its offering late Thursday at $17 a share, the midpoint of a marketed range of $16 to $18, according to a pricing term sheet filed with the Securities and Exchange Commission. Shares began trading Friday under the ticker WWB and opened at $18.35 before climbing as high as $33.99 during the session. They finished the day at $28.50, up $11.50, or roughly 67.6 percent, from the offering price. The stock slipped to $26.50 in after-hours trading, according to data compiled by the financial site StockAnalysis.
A $225 million raise, with Sanofi along for the ride
Windward sold 10,294,117 common shares in the offering, raising roughly $175 million before fees. It paired the sale with a concurrent private placement to Sanofi Foreign Participations B.V., a unit of the French drugmaker Sanofi, which agreed to buy $50 million of shares and pre-funded warrants at the same $17 price. Combined, the IPO and the Sanofi placement were expected to generate about $225 million in gross proceeds, before an over-allotment option granting underwriters the right to buy up to 1,544,117 additional shares within 30 days. Jefferies, TD Cowen, Piper Sandler and UBS Investment Bank served as joint book-running managers. The offering was expected to formally close Monday.
Friday's close valued the 38-employee company at roughly $1.65 billion, according to market data compiled by StockAnalysis and updated Saturday — nearly 70 percent above the roughly $1 billion valuation implied by the midpoint offering price before trading began. Windward's registration statement, amended as recently as Nov. 9 with the SEC, shows the company had $207.3 million in cash, cash equivalents and marketable securities as of June 30 and reported a net loss of $42.6 million for the first half of 2026, compared with a $48.3 million loss for all of 2025. A preliminary, unaudited estimate in the same filing put cash at about $181.8 million as of Sept. 30. The company has not generated any product revenue.
A long-acting bet on an already-approved drug target
Windward's lead candidate, WIN378, is a fully human antibody that blocks a signaling protein called TSLP, implicated in severe asthma and chronic obstructive pulmonary disease. It targets the same binding site as tezepelumab, the TSLP-blocking drug that Amgen and AstraZeneca sell under the brand name Tezspire, which is already approved and administered every four weeks. Windward's filing describes WIN378 as having shown greater potency than Tezspire in nonclinical studies and says its principal selling point is a half-life of up to 75 days, which the company says could support dosing only twice a year. WIN378 is currently in a Phase 2/3 trial for severe asthma, called POLARIS-1, and a separate Phase 2 trial for COPD, called SIRIUS. A second, earlier-stage candidate, WIN027, is a bispecific antibody aimed at both TSLP and the protein IL-13 and remains in a Phase 1 study in healthy volunteers.
The company's own disclosures caution that Phase 2 results "may not translate" into Phase 3 outcomes, and that Windward is relying on its Chinese and Chinese-linked licensing partners — Sichuan Kelun-Biotech, Harbour BioMed and Qyuns Therapeutics — for the accuracy of earlier nonclinical and clinical data underpinning both WIN378 and WIN027. Phase 2 primary results for the asthma program are expected in the first half of 2027, with Phase 3 enrollment slated to begin before the end of this year, according to the filing.
Part of a broader, selective reopening
Windward's debut lands amid what bankers and trade publications have called a cautious reopening of the market for new biotech stock after a prolonged drought; trade press has tallied as few as 11 biotechnology IPOs across all of 2025, among the thinnest years in over a decade. The company first filed confidentially for a U.S. listing in July and disclosed its public filing on Oct. 23, then set terms on Nov. 9 and priced the night before its debut. It follows a similar pattern set three weeks earlier by Lycia Therapeutics, a South San Francisco-based, Phase 1-stage biotech that priced its own upsized offering at $18 a share on Oct. 22 and also finished its first trading day up roughly 67 percent.
Windward's path to Nasdaq began in January 2025, when it launched with a $200 million Series A round co-led by Novo Holdings, OrbiMed and Blue Owl Healthcare Opportunities. It returned to private investors in May for a $165 million crossover round led by OrbiMed that drew in Janus Henderson, RA Capital, Harbour BioMed and Sanofi Ventures, the drugmaker's venture arm — a relationship that evidently paved the way for Sanofi's larger stake in Friday's listing. Those earlier investors, along with insiders who collectively hold about 34 percent of shares outstanding, were the most immediate beneficiaries of Friday's pop, at least on paper; a 180-day lock-up period disclosed in the registration statement prevents most existing shareholders from selling into the rally.
Among those with a stake in how Windward performs from here:
- Sanofi, which now holds shares and warrants bought in the private placement alongside its earlier venture investment, and which could become a commercial or licensing partner if WIN378 succeeds.
- Amgen and AstraZeneca, whose Tezspire franchise is the clinical and commercial benchmark Windward's pitch is built against.
- Windward's licensing partners in China, Kelun-Biotech and Harbour BioMed, whose underlying data the company says it cannot independently verify.
- The underwriting banks, which have 30 days to decide whether to exercise their option on additional shares at the $17 offering price.
What comes next
Windward's IPO is scheduled to close Monday, at which point the company will receive the bulk of its new capital. The 30-day window for underwriters to exercise their over-allotment option runs into mid-December. Investors will next watch for enrollment to begin in the Phase 3 portion of the POLARIS-1 asthma trial before year-end, followed by Phase 2 primary results across 2027, the window in which Windward's bet on infrequent dosing will begin to be tested against real clinical data rather than nonclinical comparisons to Tezspire. Little independent analyst commentary had been published on the stock by Saturday, consistent with the thin coverage that typically follows a biotech's first day of trading, though the price action itself — a market capitalization nearly 70 percent above where bankers had marketed the deal just days earlier — suggested investors were pricing in optimism about the drug's prospects well ahead of that data.

Aramark Caps Record Fiscal Year With $1 Billion Buyback, Bigger Dividend

Warren Buffett donates $5.5 billion in Berkshire stock, his largest Thanksgiving gift yet
